Tasly Biopharmaceuticals Co., Ltd. clinical trials
Acquired by China Resources Pharmaceutical Group Limited, Mar 27, 2025 · source ↗
The registry lists 9 studies whose lead sponsor is Tasly Biopharmaceuticals Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 19, 2025.
Before and after it joined China Resources Pharmaceutical Group Limited
- First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- 8
- First submitted after Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Tasly Biopharmaceuticals Co., Ltd.9 studies
Something wrong with this grouping? Tell us on the China Resources Pharmaceutical Group Limited page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All China Resources Pharmaceutical Group Limited studies →
- a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease(NAFLD)RecruitingNCT07128797Phase 1
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted after Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal CancerNot yet recruitingNCT06838546Phase 2
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruitingNCT06724263Phase 2
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid TumorsNot yet recruitingNCT05650385Phase 1
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)CompletedNCT05700591Phase 3
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy SubjectsStatus unknownNCT05655221Phase 1
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary EmbolismCompletedNCT03108833Phase 2
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)CompletedNCT03541668Phase 3
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled TrialCompletedNCT03578822Phase 3
Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited